Survival. (A) Median OS, 330 days, and 2-year 31% OS at median follow-up of 1119 days. (B) Median PFS, 184 days, and 2-year 24% PFS at median follow-up of 1502 days. (C) OS stratified by occurrence of GVHD after treatment with peg-IFNα. P = .166. Median survival 460 days for GVHD and 235 for no GVHD. (D) PFS stratified by occurrence of GVHD after treatment with peg-IFNα. P = .024. Median PFS 283 days for GVHD and 43 for no GVHD. (E) OS stratified by myeloid or nonmyeloid malignancies. P = .6226. Median survival 341 days for myeloid disease and 303 for nonmyeloid. (F) PFS stratified by disease as for panel E. P = .5999. Median survival 301 days for myeloid and 134 for nonmyeloid disease. Kaplan-Meier survival curves, with P values calculated using the log-rank (Mantel-Cox) test. *P < .05.